Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Angusta
- Development stage
- Unknown
- Lead developer
- Norgine
- Modality
- Small Molecules
- Administration
- Oral, Sublingual
01
Overview
Angusta is a low-dose (25 µg) oral tablet formulation of misoprostol, a synthetic prostaglandin E1 (PGE1) analogue, developed specifically for the induction of labour. It was originally developed by the Danish pharmaceutical company Azanta and was subsequently acquired by Norgine in 2020. Angusta is indicated for the induction of labour in pregnant women from 37 weeks of gestation who have an unfavourable cervix. It acts as an agonist at prostaglandin EP2, EP3, and EP4 receptors, which promotes cervical ripening (softening and dilation) and stimulates uterine contractions to facilitate childbirth.
- Brand names
- Angusta
02
Targets
PTGER2 (Prostaglandin E2 receptor EP2)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on Angusta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angusta.